Jade Biosciences, Inc. (NASDAQ:JBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (NASDAQ:JBIO) has a market capitalization of $1.32 Billion ($1.32 Billion) as of August 6, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7717 globally and #2282 in its home market, demonstrating a 10.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jade Biosciences, Inc.'s stock price $21.70 by its total outstanding shares 60859875 (60.86 Million). Review JBIO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
Jade Biosciences, Inc. Market Cap History: 2025 to 2026
Jade Biosciences, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $939.07 Million to $1.32 Billion (0.00% CAGR).
Jade Biosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jade Biosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of JBIO by Market Capitalization
Companies near Jade Biosciences, Inc. in the global market cap rankings as of August 6, 2026.
Key companies related to Jade Biosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Jade Biosciences, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Jade Biosciences, Inc.'s market cap moved from $939.07 Million to $ 1.32 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.32 Billion | +40.64% |
| 2025 | $939.07 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Jade Biosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.32 Billion USD |
| MoneyControl | $1.32 Billion USD |
| MarketWatch | $1.32 Billion USD |
| marketcap.company | $1.32 Billion USD |
| Reuters | $1.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more